PMID: 9166337May 1, 1997Paper

All-trans retinoic acid for the treatment of acute promyelocytic leukemia in pregnancy

Obstetrics and Gynecology
M H IncerpiJ D Byrne

Abstract

Acute promyelocytic leukemia, a subset of acute myelogenous leukemia, is commonly associated with disseminated intravascular coagulation (DIC). All-trans retinoic acid is effective in the treatment of acute promyelocytic leukemia and may prevent an exacerbation of DIC. There is limited information, however, regarding the use of this agent in pregnancy. A 29-year-old woman with acute promyelocytic leukemia and DIC at 24 weeks' gestation was treated successfully with all-trans retinoic acid during the pregnancy, delivering a viable, normal infant at 33 weeks. This case illustrates the successful use of all-trans retinoic acid in pregnancy for the treatment of acute promyelocytic leukemia. With the combined, intensive efforts of the perinatal, neonatal, and hematology-oncology services, a favorable outcome was achieved.

References

Aug 25, 1992·Annals of Internal Medicine·S R FrankelR P Warrell
May 26, 1991·The New England Journal of Medicine·R P WarrellA Jakubowski

❮ Previous
Next ❯

Citations

Feb 26, 2004·International Journal of Hematology·Ugo ConsoliRosario Giustolisi
Jun 26, 2015·Leukemia & Lymphoma·Vivek VermaVijaya Raj Bhatt
Aug 2, 2012·Birth Defects Research. Part A, Clinical and Molecular Teratology·Brady P SeligJohn J Mulvihill
May 30, 2009·Pharmacotherapy·Daisy Yang, Lindsay Hladnik
Nov 21, 2014·European Journal of Haematology·Xavier Thomas
Apr 10, 2003·Journal of Cancer Research and Clinical Oncology·F S OduncuB Emmerich

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.